Learn More
Omalizumab is a novel therapy approved for treating patients with moderate to severe persistent allergic asthma with a serum IgE ranging from 30 to 700 IU/mL. We examined the efficacy of omalizumab as a treatment for IgE-mediated food allergy. An Institutional Review Board-approved prospective pilot study was performed to assess the efficacy of omalizumab(More)
This study explored variables which predict effects of an aerobic exercise program on mood. Adult members of an eight-week conditioning program improved significantly in mood, in comparison with non-exercising controls, immediately after and three months after the program. Mood improvement was predicted by initial mood, with improvement limited to the most(More)
TO GADOLINIUM CONTRAST MEDIA Anaphylactoid reactions to gadolinium contrast media are rare, with the current literature reporting an incidence of 0.01%.1,2 We report a case of a severe anaphylactoid reaction to gadoteridol. A 58-year-old nonatopic woman with a history of breast cancer and hypertension, treated with a -blocker drug, underwent magnetic(More)
  • 1